Evidence map›Paper›PMID 41158385›Full record

ArticleJournal of thoracic disease2025

Association of systemic inflammatory markers and tertiary lymphoid structures with pathological complete response in patients with advanced lung adenocarcinoma receiving preoperative treatment: a retrospective cohort study.

Xidong Ma, Junping Sun, Mei Xie, Xugang Zhang, Xunwen Lin, Hui Deng, Aiben Huang, Fangping Ren, Yiran Liang, Jie Yao and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Xidong Ma *Department of Respiratory and Critical Care, Emergency and Critical Care Medical Center, Beijing Xuanwu Hospital, Capital Medical University, Beijing, China.
Junping Sun *Department of Pulmonary and Critical Care Medicine, The Eighth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, China.
Mei Xie *Department of Respiratory and Critical Care, Emergency and Critical Care Medical Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Xugang Zhang *Department of Thoracic Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Xunwen LinDepartment of Respiratory and Critical Care, Emergency and Critical Care Medical Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Hui DengDepartment of Respiratory and Critical Care, Emergency and Critical Care Medical Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Aiben HuangDepartment of Respiratory and Critical Care, Emergency and Critical Care Medical Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Fangping RenDepartment of Respiratory and Critical Care, Emergency and Critical Care Medical Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Yiran LiangDepartment of Respiratory and Critical Care, Emergency and Critical Care Medical Center, Beijing Xuanwu Hospital, Capital Medical University, Beijing, China.
Jie YaoDepartment of Respiratory and Critical Care, Emergency and Critical Care Medical Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Xinyu BaoDepartment of Respiratory and Critical Care, Emergency and Critical Care Medical Center, Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University, Weifang, China.
Xin ZhangDepartment of Respiratory and Critical Care, Emergency and Critical Care Medical Center, Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Shandong Second Medical University, Weifang, China.
Nuohan HanDepartment of Respiratory and Critical Care, Emergency and Critical Care Medical Center, Jining Medical University, Jining, China.
Yuanyong WangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Surgery, Peking University Cancer Hospital & Institute, Beijing, China.
Alessandro BrunelliDepartment of Thoracic Surgery, St. James's University Hospital, Leeds, UK.
Lei PanDepartment of Respiratory and Critical Care, Emergency and Critical Care Medical Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
Xinying XueDepartment of Respiratory and Critical Care, Emergency and Critical Care Medical Center, Beijing Xuanwu Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The evaluation of immune reactivity within both the tumor microenvironment (TME) and the peripheral system has become a cornerstone in assessing the efficacy of cancer therapies. Pathological complete response (pCR) is widely recognized as a key prognostic indicator following neoadjuvant treatment, yet the immune-related biomarkers predictive of pCR remain incompletely characterized. This study aims to identify and validate specific systemic and local immunological factors associated with pCR in patients undergoing antitumor therapy, thereby facilitating more precise and individualized treatment strategies. Methods: A total of 216 patients with lung adenocarcinoma scheduled to undergo radical resection of pulmonary carcinoma were retrospectively enrolled. Among them, 19 attained pCR, whereas the other 197 did not (non-pCR). A detailed evaluation of clinicopathological features via a logistic regression model identified the predictors of pCR. Hematoxylin and eosin (HE) staining, multiplex immunofluorescence (mIF), and immunohistochemistry (IHC) were performed to analyze the local immune response, in particular the tertiary lymphoid structure (TLS) features. Results: Multivariate regression results revealed that low systemic inflammation, which could be derived from a combination of decreased systemic immune-inflammation index (SII) and neutrophil-to-lymphocyte ratio (NLR), was significantly associated with pCR [odds ratio (OR): 3.26; 95% confidence interval (CI): 1.79-6.58; P=0.04]. Increased TLS density and decreased PD1 Conclusions: The local and systemic immune responses are linked to pCR. In addition, a decrease in the SII + NLR level can independently predict pCR, and certain TLS features are also associated with pCR. Immune responses should be carefully studied to optimize the preoperative treatment of patients with advanced lung adenocarcinoma.

Indexed as

Advanced lung adenocarcinomapathological complete response (pCR)preoperative treatmentsystemic inflammatory markertertiary lymphoid structure (TLS)

Identifiers

PMID41158385
PMCPMC12557612

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.